Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 1006-1011

  Hoff, Paulo M ^a   Saragiotto, Daniel F ^a   Barrios, Carlos H ^g   Del Giglio, Auro ^b   Coutinho, Anelisa K ^h   Andrade, Aline C ⁱ   Dutra, Carolina ^j   Forones, Nora M ^c   Correa, Mariangela ^d   Portella, Maria Do Socorro O ^e   Passos, Vanessa Q ^k   Chinen, Renata N ^e   Van Eyll, Brigitte ^f  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b FACULDADE DE MEDICINA DO ABC   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

^e Novartis Biociências ^*  (Brazil)

^f Instituto do Cancer Dr Arnaldo   (Brazil)

^g PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^h Clínica de Assistência Multidisciplinar em Oncologia AMO   (Brazil)

ⁱ Biocancer SA   (Brazil)

^j Centro Nacional de Pesquisa   (Brazil)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; OXALIPLATIN; ANTIDIARRHEAL AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED DIARRHEA; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMICOLECTOMY; HOSPITALIZATION; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; ANTIDIARRHEALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DELAYED-ACTION PREPARATIONS; DEOXYCYTIDINE; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; LOPERAMIDE; MALE; MIDDLE AGED; OCTREOTIDE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84901648923     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.8077     Document Type: Article

References (34)

1. Wadler S, Benson AB 3rd, Engelking C, et al: Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16:3169-3178, 1998 (Pubitemid 28417440)
2. Classen J, Belka C, Paulsen F, et al: Radiationinduced gastrointestinal toxicity: Pathophysiology, approaches to treatment and prophylaxis. Strahlenther Onkol
3. Townsley CA, Major P, Siu LL, et al: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94:1136-1143, 2006
4. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
5. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19:3801-3807, 2001 (Pubitemid 32880058)
6. Benson AB 3rd, Ajani JA, Catalano RB, et al: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918-2926, 2004 (Pubitemid 41079912)
7. Gorden P, Comi RJ, Maton PN, et al: NIH conference: Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110:35-50, 1989 (Pubitemid 19032792)
8. Barbounis V, Koumakis G, Vassilomanolakis M, et al: Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9:258-260, 2001 (Pubitemid 32537284)
9. Cascinu S, Fedeli A, Fedeli SL, et al: Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: A randomized trial. J Clin Oncol 11:148-151, 1993 (Pubitemid 23059987)
10. Cascinu S, Fedeli A, Fedeli SL, et al: Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 28:482-483, 1992
11. Gebbia V, Carreca I, Testa A, et al: Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 4:443-445, 1993 (Pubitemid 23253701)
12. Goumas P, Naxakis S, Christopoulou A, et al: Octreotide acetate in the treatment of fluorouracil-induced diarrhea. Oncologist 3:50-53, 1998 (Pubitemid 28106722)
13. Pro B, Lozano R, Ajani JA: Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs 19:341-343, 2001 (Pubitemid 32782976)
14. Zidan J, Haim N, Beny A, et al: Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 12:227-229, 2001 (Pubitemid 32223873)
15. Maroun JA, Anthony LB, Blais N, et al: Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 14:13-20, 2007
16. Ippoliti C, Champlin R, Bugazia N, et al: Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol 15:3350-3354, 1997 (Pubitemid 27485854)
17. Ippoliti C, Neumann J: Octreotide in the management of diarrhea induced by graft versus host disease. Oncol Nurs Forum 25:873-878, 1998
18. Yavuz MN, Yavuz AA, Aydin F, et al: The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: A randomized controlled study. Int J Radiat Oncol Biol Phys 54:195-202, 2002
19. Rosenoff S: Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer 12:561-570, 2004
20. Rosenoff SH: Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. Eur J Cancer Care (Engl) 13:380-383, 2004
21. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25:4779-4786, 2007 (Pubitemid 350086481)
22. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005 (Pubitemid 46223991)
23. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
24. Sastre J, Marcuello E, Masutti B, et al: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23:3545-3551, 2005
25. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001 (Pubitemid 32366981)
26. Bajetta E, Di Bartolomeo M, Mariani L, et al: Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100:279-287, 2004 (Pubitemid 38063635)
27. Borner MM, Bernhard J, Dietrich D, et al: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. Ann Oncol 16:282-288, 2005 (Pubitemid 40309311)
28. Cartwright T, Lopez T, Vukelja SJ, et al: Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5:50-56, 2005
29. Kim TW, Kang WK, Chang HM, et al: Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group trial. Acta Oncol 44:230-235, 2005 (Pubitemid 40904125)
30. National Comprehensive Network: Metastatic Colorectal Cancer: NCCN Clinical Practice Guideline in Oncology, Version 1.2012, August 30, 2011. National Comprehensive Network 2011
31. Rosenoff SH, Gabrail NY, Conklin R, et al: A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: Results of the STOP trial. J Support Oncol 4:289-294, 2006 (Pubitemid 44203632)
32. Zachariah B, Gwede CK, James J, et al: Octreotide acetate in prevention of chemoradiationinduced diarrhea in anorectal cancer: Randomized RTOG trial 0315. J Natl Cancer Inst 102:547-556, 2010
33. Martenson JA, Halyard MY, Sloan JA, et al: Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: Results of North Central Cancer Treatment Group N00CA. J Clin Oncol 26:5248-5253, 2008
34. Chen T, Miller TF, Prasad P, et al: Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol 40:475-481, 2000